Impact of copper compression stockings on venous insufficiency and lipodermatosclerosis: A randomised controlled trial

Phlebology. 2019 May;34(4):224-230. doi: 10.1177/0268355518795329. Epub 2018 Aug 27.

Abstract

Objective: Compression stockings are the primary treatment for lipodermatosclerosis secondary to chronic venous disease, but do not improve the skin condition. The aim of this study was to investigate the impact of copper on lipodermatosclerosis.

Methods: A double-blind randomised controlled pilot study was performed including patients with bilateral lipodermatosclerosis. One compression stocking of a pair was impregnated with copper. Symptom score and surface area of lipodermatosclerosis were assessed at baseline, after 2, 4 and 8 weeks.

Results: Sixteen patients were included. There was no significant difference in mean symptom scores; however, there was a significant reduction of the surface area in the study group 42,637 to 35,739 mm2 versus 41,487 to 43,210 mm2 in the control group (p = 0.04).

Conclusion: This study demonstrates the beneficial effect of copper on lipodermatosclerosis secondary to chronic venous disease with reduction in surface area but no benefit on symptoms. Trials identification number: NCT03283800.

Keywords: Chronic venous disease; compression therapy; copper; lipodermatosclerosis; randomised controlled trial.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Aged
  • Aged, 80 and over
  • Copper*
  • Dermatitis / etiology
  • Dermatitis / pathology
  • Dermatitis / therapy*
  • Double-Blind Method
  • Female
  • Humans
  • Male
  • Middle Aged
  • Scleroderma, Localized / etiology
  • Scleroderma, Localized / pathology
  • Scleroderma, Localized / therapy*
  • Stockings, Compression*
  • Varicose Ulcer / complications
  • Varicose Ulcer / pathology
  • Varicose Ulcer / therapy*
  • Venous Insufficiency / complications
  • Venous Insufficiency / pathology
  • Venous Insufficiency / therapy*

Substances

  • Copper

Supplementary concepts

  • Lipodermatosclerosis

Associated data

  • ClinicalTrials.gov/NCT03283800